Strategy To Tether Organometallic Ruthenium-Arene Anticancer Compounds to Recombinant Human Serum Albumin

In order to utilize macromols. for drug targeting and delivery, a strategy to tether organometallic ruthenium-arene drugs to carrier protein mols. was developed. The approach involves the design of a drug fragment capable of conjugating to linker mols. on a modified carrier protein via hydrazone bond formation. The proof-of-concept using recombinant human serum albumin is described.